Partners invited to apply for allocation of new CIMMYT pre-commercial hybrids

The International Maize and Wheat Improvement Center (CIMMYT) is offering a new set of improved maize hybrids to partners in southern Africa and similar agro-ecological zones, to scale up production for farmers in these areas.

National agricultural research systems and seed companies are invited to apply for the allocation of these pre-commercial hybrids, after which they will be able to register, produce and offer the improved seed to farming communities.

The deadline for applications is November 1^st, 2017.

CIMMYT Improved Maize Product Allocation Application Form (v20170214).

2017 CIMMYT-SARO product announcement.

Additional information:

Table 1. 2017 CIMMYT SARO trial site information

Table 2. Mean yield performance and agronomic attributes of available elite early/extra-early maturing CIMMYT hybrids and commercial and internal genetic check hybrids in southern Africa 2017 regional trial (EHYB17)

Table 3. Mean yield performance and agronomic attributes of available elite Medium maturing CIMMYT hybrids and commercial and internal genetic check hybrids in southern Africa 2017 regional trial (IHYB17) 

Table 4. Mean yield performance and agronomic attributes of available elite late maturing CIMMYT hybrids and commercial and internal genetic check hybrids in southern Africa 2017 regional trial (LHYB17)

Table 5. Mean yield performance and agronomic attributes of available elite early/extra-early maturing WEMA hybrids and commercial and internal genetic check hybrids in southern Africa 2017 regional trial (WEHYB17)

Table 6. Mean yield performance and agronomic attributes of available elite Medium-late maturing WEMA hybrids and commercial and internal genetic check hybrids in southern Africa 2017 regional trial (WLHYB17)

Table 7. Mean yield performance, agronomic attributes and quality parameters of available elite medium-late maturing CIMMYT QPM hybrids and commercial and internal genetic check hybrids in southern Africa 2017 regional trial (ADVQPM17)